

1 **Title:** Analysis of phage therapy failure in a patient with a *Pseudomonas*
2 *aeruginosa* prosthetic vascular graft infection

3

4 **Authors:** Lucia Blasco¹, Inmaculada López-Hernández^{2,3}, Miguel Rodríguez-
5 Fernández⁴, Javier Pérez-Florido^{5,6}, Carlos S. Casimiro-Soriguer^{5,6}, Sarah
6 Djebara⁷, Maya Merabishvili⁷, Jean-Paul Pirnay⁷, Jesús Rodríguez-Baño^{2,3},
7 María Tomás^{1&*}, Luis Eduardo López Cortés^{2,3&}

8

9 1. Translational and Multidisciplinary Microbiology (MicroTM)-Biomedical
10 Research Institute (INIBIC); Microbiology Service, A Coruña Hospital (HUAC);
11 University of A Coruña (UDC), A Coruña, Spain.

12 2. Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital
13 Universitario Virgen Macarena; Departamentos de Medicina y Microbiología,
14 Facultad de Medicina, Universidad de Sevilla; and Instituto de Biomedicina de
15 Sevilla (IBiS)/CSIC, Seville, Spain.

16 3. CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain

17 4. Unit of Infectious Diseases and Microbiology, Valme University Hospital,
18 Institute of Biomedicine of Sevilla, Seville, Spain.

19 5. Computational Medicine Platform, Andalusian Public Foundation Progress and
20 Health-FPS, 41013 Sevilla, Spain

21 6. Computational Systems Medicine, Institute of Biomedicine of Seville, IBiS,
22 University Hospital Virgen del Rocío/CSIC/University of Sevilla, 41013 Sevilla,
23 Spain

24 7. Laboratory for Molecular and Cellular Technology, Queen Astrid Military
25 Hospital, Neder-over-Heembeek, Belgium

26

27 &These researchers contributed equally to the work as senior authors

28 *Correspondence: Maria Tomás

29 Email: MA.del.Mar.Tomas.Carmona@sergas.es;

30 Tel.: +34 981176399; Fax: +34 981178273.

31

32 **Keywords:** Phage; phage therapy; antibiotic resistance; *Pseudomonas*
33 *aeruginosa*; bypass; prosthetic vascular graft infection

34

37 Abstract

38 Clinical case of a patient with a *Pseudomonas aeruginosa* multidrug-resistant
 39 prosthetic vascular graft infection which was treated with a cocktail of phages
 40 (PT07, 14/01 and PNM) in combination with ceftazidime-avibactam (CAZ/AVI).
 41 After the application of the phage treatment and in absence of antimicrobial
 42 therapy, a new *P. aeruginosa* bloodstream infection (BSI) with a septic residual
 43 limb metastasis occurred, now involving a wild-type strain being susceptible to
 44 β -lactams and quinolones. Clinical strains were analyzed by microbiology and
 45 whole genome sequencing techniques. In relation with phage administration,
 46 the clinical isolates of *P. aeruginosa* before phage therapy (HE2011471) and
 47 post phage therapy (HE2105886) showed a clonal relationship but with
 48 important genomic changes which could be involved in the resistance to this
 49 therapy. Finally, phenotypic studies showed a decreased in Minimum Inhibitory
 50 Concentration (MIC) to β -lactams and quinolones as well as an increase of the
 51 biofilm production and phage resistant mutants in the clinical isolate of *P.*
 52 *aeruginosa* post phage therapy.

53 Importance

54 Phage therapy is a promising new treatment against infections produced by
 55 multi-drug resistant pathogens. For that, it would be necessary to know more
 56 about the clinical response and host-phage interactions by massive sequencing
 57 techniques to improve phage therapy application. In this work, we analyzed the
 58 clinical, microbiological and molecular features of the *P. aeruginosa* isolates in
 59 prosthetic vascular graft infection after the phages administration failure against
 60 this infection. This knowledge could allow to develop strategies of improvement
 61 of the use of phage therapy as treatment of multiple clinical infections.

62

63

64

65

66

We present the case of a in their 50s man who in July 2020 developed a surgical infection caused by ceftazidime and piperacillin-tazobactam resistant *Pseudomonas aeruginosa*. In August 2020, an axillo-bifemoral bypass was performed. Shortly afterwards, the patient developed a bloodstream infection (BSI) caused by *P. aeruginosa* with the same antibiotic resistance pattern, originating from a sacral ulcer, which was treated with meropenem (1g, q8h for 17 days). The patient suffered up to five recurrences of *P. aeruginosa* BSI between October and December 2020, while the sacral ulcer developed favourably. After the second relapse, 18F-fluorodeoxyglucose (18F-FDG) PET/CT was performed, showing pathological radioactive-labelled glucose uptake along the preclavicular graft region (SUVmax value, 5.29) and suggesting prosthetic vascular graft infection (PVGI). Nevertheless, surgical management was rejected. The patient subsequently received different targeted antibiotherapies for two to six weeks (Figure 1). Two new *P. aeruginosa* BSI relapses occurred between March and May 2021. Ceftolozane-tazobactam was not used (not available), and off-label tebipenem use was denied; treatment was therefore as shown in Figure 1. Simultaneously, therapeutic phages were obtained from the Queen Astrid Military Hospital (Brussels, Belgium) in view of a possible compassionate use phage therapy. Phage susceptibility of the clinical isolate was determined in the A Coruña University Hospital, and three *P. aeruginosa* phages (PT07, 14/01 and PNM) were selected [1, 2]. In July 2021, 70 ml of the bacteriophage cocktail, consisting of the three phages, each at a concentration of 10^7 plaque forming units (PFU)/mL, was administered intravenously, once a day in a 6-hour infusion for three days in an inpatient regimen. No adverse events were observed. Phage therapy was followed by four days of outpatient parenteral antimicrobial therapy (OPAT) at the patient's request. Ceftazidime-avibactam was applied for 8 weeks (6 weeks before and 2 weeks after the phage therapy). In August 2021, in the absence of antimicrobial therapy, a new *P. aeruginosa* BSI with a septic residual limb metastasis occurred, now involving a wild-type strain being susceptible to β -lactams and quinolones. Finally, upon a multidisciplinary discussion, a proximal vascular prosthesis replacement combined with antibiotherapy in OPAT was performed. Currently, after ten months without treatment, the patient remains asymptomatic.

101 Eight blood culture isolates obtained between November 2020 and August 2021
 102 were characterized by microbiological analysis. These isolates were identified
 103 by matrix assisted laser desorption/ionisation - time of flight mass spectrometry
 104 (MALDI-TOF MS, Bruker Daltonics) as *P. aeruginosa*. Antimicrobial
 105 susceptibility testing was performed by broth microdilution (Microscan,
 106 Beckman Coulter) and interpreted using European Committee on Antimicrobial
 107 Susceptibility Testing (EUCAST) criteria. Pulsed-field gel electrophoresis
 108 (PFGE) revealed that four representative isolates from 2020 and 2021, were
 109 clonal (Figure S1). Genomic sequence of five representative isolates showed
 110 that these isolates belonged to the high-risk clone ST308 with core genome
 111 MLST (MLST)cgST2675. A search for antimicrobial resistance genes in the
 112 ResFinder database did not identify any acquired resistance genes such as β -
 113 lactamases. Analysis of 40 chromosomal resistance genes revealed natural
 114 polymorphisms in numerous genes, including some changes with unknown
 115 effect [3]. The profile of all isolates was identical for all genes studied, except for
 116 the *nfxB* gene (a transcriptional repressor that regulates MexCD-OprJ), in which
 117 multiple amino acid changes were observed in the last 3 isolates (Table S1,
 118 Figure S2). Moreover, comparison of the genomes of isolates HE2011471
 119 (previous to phage administration) and HE2105886 (one month after phage
 120 treatment) revealed important mutations (Figure 2). Interestingly, several
 121 detected genomic changes could be involved in phage resistance (Table S2,
 122 Figure 3). Isolate HE2105886, recovered one month after phage treatment,
 123 exhibited a decrease in the Minimum Inhibitory Concentration (MICs) of β -
 124 lactam and quinolone antibiotics (Figure 1), an increased biofilm formation
 125 (Figure S3A), and an increased frequency of occurrence of phage resistant
 126 mutants (Figure S3B) [4].

127 DISCUSSION

128 This case highlights three key issues. The first relates to the use of combined
 129 therapy versus monotherapy as a definitive treatment for *P. aeruginosa* BSI. So
 130 far, combination therapy has not been associated with reduced mortality or any
 131 advantages in terms of clinical outcome or successful treatment of
 132 recurrent/persistent bacteraemia [5]. The second issue concerns prosthetic
 133 vascular graft infection (PVGI) diagnosis and its best management. At the early

134 stages of PVGI, a high degree of suspicion is essential. Indium-111-labelled
 135 white blood cell scintigraphy plus single-photon emission computed tomography
 136 (SPECT/CT) could reduce the false positive rates observed with PET/CT [6]. In
 137 the present case, PET/CT was not performed at the early postoperative stage,
 138 because of the possibility of a false positive result. Regarding the treatment,
 139 graft excision is the preferred surgical approach. However, some patients are
 140 considered unacceptable surgical candidates due to underlying comorbidities or
 141 technically unfeasible surgery. When this occurs, lifelong suppressive
 142 antimicrobial therapy is an option, but is not free of side-effects or the risk of
 143 development of antimicrobial resistance. As the patient was initially denied
 144 surgical treatment, long-term suppressive treatment with quinolones was
 145 administered. However, ciprofloxacin-resistance developed, and surgery was
 146 finally deemed key to a favourable outcome. Furthermore, there is no evidence-
 147 based recommendation for either PVGI antimicrobial treatment or its optimal
 148 duration; minimum intravenous therapy for 6 weeks followed by oral
 149 antibiotherapy for up to 6 months has been proposed [7, 8]. ¹⁸F-FDG PET/CT-
 150 guided treatment duration seems feasible and would allow treatment to be
 151 tailored to individual patients [9]. The third highlighted issue is related to phage
 152 therapy. Phage therapy involves the targeted application of strictly virulent
 153 phages that can specifically infect and lyse the targeted pathogenic bacteria
 154 they encounter, hereby releasing virion progeny that continues the lytic cycle. A
 155 major advantage of phages is the minimal impact on non-target bacteria or body
 156 tissues [10]. A recent systematic review suggested that phage therapy is safe
 157 and may be effective in different difficult-to-treat infections [11]. Interestingly, a
 158 previously-reported case of β -lactam resistance in an MDR *P. aeruginosa*
 159 isolate causing an aortic graft infection was reverted after treatment with a
 160 phage that appeared to utilize the outer membrane protein M (OprM) of the
 161 MexAB- and MexXY-multidrug efflux pumps, associated with antibiotic
 162 resistance, as a receptor, and which was no longer expressed in the selected
 163 phage-resistant bacterial strain [12]. In the present case, even though phage
 164 therapy did not cure the infection, the posterior infection recurrence was caused
 165 by an antibiotic susceptible isolate that belonged to the same lineage as the one
 166 that was causing the pre-phage treatment episodes of infection. However, the
 167 recurrent isolate was recovered one month after the phage therapy, and it is

possible that the resensitization (to β -lactams and quinolones) could have been due to a spontaneous evolution of the resident strain. Further studies are necessary to elucidate whether the genomic changes found in the bacteria are responsible for the change in phenotype and are related to the phage therapy. One strength of this study is that phage therapy was able to be safely administered in OPAT for greater patient convenience. To our knowledge, this has only been reported once before, in a series of six cases, without phage-related adverse events [13]. The main limitations our study were: first, we did not perform in vitro studies of the effect of the phages in combination with antibiotics, specially β -lactams; second, we could not study the *P. aeruginosa* clinical isolates during the seven days of application of phage therapy. Finally, it should be noticed that there are no national or local phage bank with characterized phages against *P. aeruginosa* in which specific phages could be selected to provide personalized approach in patients with complex infections caused by these bacteria. In conclusion, in complex *P. aeruginosa* infections the choice of antibiotic therapy and its duration are crucial for minimizing antibiotic pressure and development of resistance. Although we have not demonstrated that phage treatment was effective in this case, studying the molecular mechanisms of resistance to phages and bacteria-phage interactions are key to improving phage therapy in the near future.

MATERIAL/METHODS

Microbiology studies

The isolates were identified by MALDI-TOF MS (Bruker Daltonics). Antimicrobial susceptibility testing was performed by broth microdilution with a Microscan system (Beckman Coulter), and the results were interpreted according to the clinical breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). PFGE analysis was performed using *Spel*.

Genomic sequencing and bioinformatic tools

Whole genome sequencing of the five isolates was performed in a HiSeq 2500 sequencing system (Illumina), and sequences were assembled using SPAdes 3.10.1.

200 Clonality testing of genomes was carried out using MLST Finder (from CGE,
201 available at <https://bitbucket.org/genomicepidemiology/mlst/src/master/>) and
202 Ridom SeqSphere+ v8.5, and the resistance mechanisms were analyzed using
203 the ResFinder database. SNP calling was performed using snippy v4.6.0
204 against the NCBI PGAP annotation
205 (https://www.ncbi.nlm.nih.gov/genome/annotation_prok/). The assemblies were
206 visually inspected using Bandage v0.8.1. (<https://rrwick.github.io/Bandage/>).
207 Further functional annotation genes and prophage elements were confirmed
208 using Blastx (<http://blast.ncbi.nlm.nih.gov>), Hmmer (<http://hmmer.org>) and also
209 the HHpred tool (<https://toolkit.tuebingen.mpg.de/tools/hhpred>), which predict
210 functions through protein structure.

211 Assembled genomes of *P. aeruginosa* isolates were analyzed using Phaster
212 (PHAge Search Tool Enhanced Release) software (<https://phaster.ca/>) and
213 SourceFinder (<https://cge.food.dtu.dk/services/SourceFinder/>).

214 **Biofilm production**

215 Overnight cultures of *P. aeruginosa* isolates HE2011471 and HE2105886 were
216 diluted 1:100 and used to inoculate 100 µL of LB broth in a 96 multi-well plate.
217 The plate was incubated for 24 h at 37 °C in darkness. The supernatant was
218 discarded and the wells were washed with PBS. One hundred µL of methanol
219 was then added to each well and discarded after 10 min. When the methanol
220 had completely evaporated, 100 µL of crystal violet (0.1%) was added and
221 discarded after 15 min. Finally, the wells were washed with PBS before the
222 addition of 150 µL of acetic acid (30%), and the absorbance was measured at
223 OD 585 nm.

224 **Frequency of occurrence of phage resistant mutants**

225 The frequency of occurrence of phage resistant mutants was determined as
226 previously described, with some modifications [14]. Overnight cultures of
227 isolates HE2011471 and HE 2105886 were diluted 1:100 in LB and grown to an
228 OD_{600nm} of 0.6–0.7. An aliquot of 100 µL of the culture containing 10⁸ colony
229 forming units (CFU)/mL was serially diluted, and each dilution was mixed with
230 100 µL of 10⁹ PFU/mL phage cocktail and then plated by the agar overlay
231 method [15]. The plates were incubated at 37 °C for 18 h and the number of

CFUs was counted. The frequency of occurrence of phage resistant mutants and phage resistant mutants was calculated by dividing the number of resistant bacteria by the total number of sensitive bacteria.

ACKNOWLEDGEMENTS

We are grateful to Juan Manuel Carmona-Caballero (Hospital Universitario Virgen del Rocío), Elena Fraile (Hospital Universitario Virgen del Rocío), Vicente Merino-Bohorquez (Hospital Universitario Virgen Macarena) and Zaira Palacios-Baena (Hospital Universitario Virgen Macarena) for clinical assistance. We also thank to Carlos Velázquez-Velázquez (Hospital Universitario Virgen Macarena) and Jose Miguel Barquero-Aroca (Hospital Universitario Virgen Macarena) for the surgical assistance. Phage studies were financed by grants PI19/00878 and PI22/00323 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (CIBER CB21/13/00012 and CIBER project PMP22/00092), and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, <http://www.seimc.org/>). L.E.L.C. and J.R.B. were supported by Plan Nacional de I+D+I 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001)-co-financed by European Development Regional Fund 'A way to achieve Europe, Operative program Intelligent Growth 2014-2020'.

TRANSPARENCY DECLARATIONS

The authors declare that they have no conflicts of interest.

DATA AVAILABILITY

All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Bacterial genomes of *Pseudomonas aeruginosa* isolates HE2105886 (after phage treatment) in

comparison with HE2011471 (previous to phages administration) are deposited in the GenBank Bioproject PRJNA938043 (<https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA938043>).

ETHICAL APPROVAL

Medical Direction of Hospital Universitario Virgen Macarena approved the phage therapy in this patient and after signing the informed consent by the patient by use of experimental medication as compassionate use.

FIGURES

Figure 1. Timeline depicting the different antibiotic and phage therapies, the isolation of *Pseudomonas aeruginosa* strains from blood cultures and their antibiotic susceptibility and genomic analyses. PFGE of these strains is described in the Figure S1. ¹Completed in outpatient parenteral antibiotic treatment. ²CAZ/AVI: Ceftazidime-avibactam. ³MIC: Minimum inhibitory concentration. ⁴P/T: Piperacillin-tazobactam. Whole Genome Sequences (WGS) is shown in Black Genome Sequences (three clinical isolates) and Red Genome Sequences, which are bacterial genomes of *Pseudomonas aeruginosa* isolates in relation with phage therapy (two clinical isolates): HE2105886 (after phage treatment) in comparison with HE2011471 (prior to phage administration).

Figure 2. Circular chromosomic view of the bacterial genomes of two *Pseudomonas aeruginosa* isolates: HE2105886 (after phage treatment) in comparison with HE2011471 (prior to phage administration).

Figure 3. Graphic representation of the proteins coded by the HE2105886 genome with an emphasis of changes associated with mechanisms of resistance and response to phage infection.

SUPPLEMENTARY MATERIAL

Figure S1. PFGE (*Pulsed Field Gel Electrophoresis*) patterns of four sequential *Pseudomonas aeruginosa* isolates.

Figure S2. Amino acid changes in NfxB.

294 **Figure S3.** Comparison of the biofilm production (A) and the frequency of
 295 occurrence of phage resistant mutants(B) between the *Pseudomonas*
 296 *aeruginosa* isolates HE2011471 (pre phage therapy) and HE2105886 (post
 297 phage therapy). **** p value < 0.001 (GraphPad Prism 9.0.0).

298 **Table S1.** Mutations encountered in proteins known to be related to
 299 antimicrobial resistance in *Pseudomonas aeruginosa*.

300 **Table S2.** Mutations encountered in proteins supposed to be related to
 301 phage resistance in response to lytic phage infection in *P.*
 302 *aeruginosa*. ^a Proteins located in prophages as identified by Phaster and
 303 SourceFinder.

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321 REFERENCES

- 322 1. PJ Ceyssens, T Glonti, NM Kropinski, R Lavigne, N Chanishvili, L Kulakov, et
323 al. Phenotypic and genotypic variations within a single bacteriophage species.
324 Virol J. 2011; 8:134. <https://doi.org/10.1186/1743-422X-8-134>.
- 325 2. PJ Ceyssens, K Miroshnikov, W Mattheus, V Krylov, J Robben, JP Noben, et
326 al. Comparative analysis of the widespread and conserved PB1-like viruses
327 infecting *Pseudomonas aeruginosa*. Environ Microbiol. 2009; 11(11): 2874-83.
328 <https://doi.org/10.1111/j.1462-2920.2009.02030.x>.
- 329 3. Cortes-Lara S, Barrio-Tofiño ED, López-Causapé C, Oliver A; GEMARA-
330 SEIMC/REIPI *Pseudomonas* study Group. Predicting *Pseudomonas aeruginosa*
331 susceptibility phenotypes from whole genome sequence resistome analysis.
332 Clin Microbiol Infect. 2021 Nov;27(11):1631-1637.
333 <https://doi.org/10.1016/j.cmi.2021.05.011>
- 334 4. M Castledine, D Padfield, P Sierocinski, J Soria Pascual, A Hughes, L
335 Mäkinen, et al. Parallel evolution of *Pseudomonas aeruginosa* phage resistance
336 and virulence loss in response to phage treatment in vivo and in vitro. Elife.
337 2022; 11: e73679. <https://doi.org/10.7554/eLife.73679>
- 338 5. Babich T, Naucier P, Valik JK, Giske CG, Benito N, Cardona R, et al.
339 Combination versus monotherapy as definitive treatment for *Pseudomonas*
340 *aeruginosa* bacteraemia: a multicentre retrospective observational cohort study.
341 J Antimicrob Chemother. 2021; 76 (8): 2172-81.
342 <https://doi.org/10.1093/jac/dkab134>
- 343 6. Reinders Folmer EI, Von Meijenfildt GCI, Van der Laan MJ, Glaudemans
344 AWJM, Slart RHJA, Saleem BR, et al. Diagnostic Imaging in Vascular Graft
345 Infection: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg.
346 2018; 56 (5): 719-29. <https://doi.org/10.1016/j.ejvs.2018.07.010>
- 347 7. Leroy O, Meybeck A, Sarraz-Bournet B, d'Elia P, Legout L. Vascular graft
348 infections. Curr Opin Infect Dis. 2012; 25 (2): 154-8. <https://doi.org/10.1097/QCO.0b013e3283501853>

- 350 **8.** Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O’Gara PT, Lockhart
351 PB, et al. Vascular Graft Infections, Mycotic Aneurysms, and Endovascular
352 Infections: A Scientific Statement From the American Heart Association.
353 Circulation. 2016; 134 (20): e412-60. [https://doi.org/](https://doi.org/10.1161/CIR.0000000000000457)
354 [10.1161/CIR.0000000000000457](https://doi.org/10.1161/CIR.0000000000000457).
- 355 **9.** Kung BT, Seraj SM, Zadeh MZ, Rojulpote C, Kothekar E, Ayubcha C, et al.
356 An update on the role of ¹⁸F-FDG-PET/CT in major infectious and inflammatory
357 diseases. Am J Nucl Med Mol Imaging. 2019; 9 (6): 255-73. [eCollection 2019](https://doi.org/10.1161/CIR.0000000000000457).
- 358 **10.** Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human
359 infections. Bacteriophage. 2011; 1 (2): 66-85. [https://doi.org/](https://doi.org/10.4161/bact.1.2.15845)
360 [10.4161/bact.1.2.15845](https://doi.org/10.4161/bact.1.2.15845).
- 361 **11.** Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et
362 al. Safety and efficacy of phage therapy in difficult-to-treat infections: a
363 systematic review. Lancet Infect Dis. 2022; S1473-3099(21)00612-5.
364 [https://doi.org/10.1016/S1473-3099\(21\)00612-5](https://doi.org/10.1016/S1473-3099(21)00612-5).
- 365 **12.** Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D.
366 Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. Evol
367 Med Public Health. 2018; 2018 (1): 60-6. <https://doi.org/10.1093/emph/eoy005>.
- 368 **13.** Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, et al.
369 Lessons Learned from the First 10 Consecutive Cases of Intravenous
370 Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a
371 Single Center in the United States. Open Forum Infect Dis. 2020; 7 (9):
372 ofaa389. <https://doi.org/10.1093/ofid/ofaa389>.
- 373 **14.** Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R,
374 Ramos-Vivas J, Coenye T, Fernandez-Cuenca F, Vila J, Martinez-Martinez L,
375 Rodriguez-Baño J, Pascual A, Cisneros JM, Pachon J, Bou G, Tomas M.
376 Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different
377 Antibiotics in Clinical Isolates of Multi-Resistant *Acinetobacter baumannii*.
378 Microorganisms. 2019 Nov 12;7(11):556. [https://doi.org/](https://doi.org/10.3390/microorganisms7110556)
379 [10.3390/microorganisms7110556](https://doi.org/10.3390/microorganisms7110556).

380 **15.** Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP.
381 Enumeration of bacteriophages by double agar overlay plaque assay. Methods
382 Mol Biol. 2009; 501:69-76. https://doi.org/10.1007/978-1-60327-164-6_7.

383

384




Figure 1.






Figure 2.




Antibiotic Susceptibility and Ion Transport

- FemA receptor
- TonB-Dependent receptor
- CorC ion transport
- AcrR/LysR regulators



Quorum Sensing Activation

- PvdQ-QQ enzyme




Phage Infection Inhibition



- FemA receptor
- TonB-Dependent Receptor

Secretion Systems


- Agglutinin-T1SS
- ExsC activator-T3SS
- VgrG effector-T6SS



Response Oxidative Stress



- Occludens toxin-Filamentous prophage induction
- HipBA TA systems
- SAM-dependent methyltransferase YafE



390

391

Figure 3.




Figure S1.

CLUSTAL O(1.2.4) multiple sequence alignment

```

PA01nfxB      -----MTLISHDERLIKALAVAIVDPRATLKELAEAAGVSKA      38
HE2011311    MTLAPRSAQLPDSPHKDSLDPAPTSSQDQRLKALATAMVNHPRATMGELAGVSRA      60
HE2011471    MTLAPRSAQLPDSPHKDSLDPAPTSSQDQRLKALATAMVNHPRATMGELAGVSRA      60
HE2105886    MTLAPRSAQLPDSPHKDSLDPAPTSSQDQRLKALATAMVNHPRATMGELAGVSRA      60
               *  *:***:****.*:*::*****:  ****  ****:*

PA01nfxB      TLHRFCGTRDNLVQMLEDHGETVLNQIIQACDLEHAEPLAQLRIKEHLTHRELLVFLV      98
HE2011311    TLNRHCGTREGLKRRLESHARSTLERLTHSAALQRLEPREALRELIREHLAQRDLLALLM      120
HE2011471    TLNRHCGTREGLKRRLESHARSTLERLTHSAALQRLEPREALRELIREHLAQRDLLALLM      120
HE2105886    TLNRHCGTREGLKRRLESHARSTLERLTHSAALQRLEPREALRELIREHLAQRDLLALLM      120
               **:*.****:.*  :  **.*.***:***:  ::.  *:  **  ***:.*:****:***:***:***:***:


PA01nfxB      FQYRPDFLDPHGEGARWQSYLEALDAFFLRGQQKGVFRIDITAAVFTELFITLVYGMVDA      158
HE2011311    FEQNPGRHAGHGD-ASWQSYVEALDAFFLRGQQKRVFRIDISAATFSELFIVLIYGMVDA      179
HE2011471    FEQNPGRHAGHGD-ASWQSYVEALDAFFLRGQQKRVFRIDISAATFSELFIVLIYGMVDA      179
HE2105886    FEQNPGRHAGHGD-ASWQSYVEALDAFFLRGQQKRVFRIDISAATFSELFIVLIYGMVDA      179
               *:  *.      **:  *  ****:*****  *****:***.*:****.*:*****

PA01nfxB      ERRGRAASSNSAHTLEQMFLHGASNPARS---      187
HE2011311    ERRGRAASAGLSATLEELFLRGASNPAQPASP      211
HE2011471    ERRGRAASAGLSATLEELFLRGASNPAQPASP      211
HE2105886    ERRGRAASAGLSATLEELFLRGASNPAQPASP      211
               *****:.*  :  ***:***:*****:

```

Figure S2.

A



B

HE2011471	HE2105886
$1.23 \pm 0.11 \times 10^{-6}$	$8.36 \pm 0.23 \times 10^{-4}$

Figure S3.

Protein	Mechanism	Mutations ¹
AmpC	Structural change	G27D, T105A, V205L, V356I, G391A
AmpD	AmpC overexpression	None
AmpDh2	AmpC overexpression	V40I
AmpDh3	AmpC overexpression	None
AmpR	AmpC overexpression	G283E, M288R
ArmZ	MexXY overexpression	C40R, L88P, S112N, D119E, I237V, V243A
DacB	AmpC overexpression	None
DacC	PBP5	None
FtsI	PBP3	G8S
FusA1	Elongation factor G	H166D
GalU	Lipopolisaccharide synthesis	None
GyrA	DNA gyrase (subunit A)	None
GyrB	DNA gyrase (subunit B)	S466F
MexA	Intrinsic antibiotic resistance	A111T
MexB	Intrinsic antibiotic resistance	G957D, S1041E, V1042A
MexC	MexCD overexpression	E251Q,A262E,A277T,H310R,S330A,A378T,A384V
MexD	MexCD overexpression	T87S,S845A
MexE	MexEF overexpression	None
MexF	MexEF overexpression	None
MexR	MexAB overexpression	M1_L13del, V132A

420	MexS	MexEF overexpression/OprD downregulation	V73A, D249N
	MexT	MexEF overexpression/OprD downregulation	M1_A78del, F172I
421	MexX	Intrinsic antibiotic resistance	A30T, K329Q, L331V, W358R
422	MexY	Intrinsic antibiotic resistance	I536V, T543A, G589A, Q840E, N1036T
	MexZ	MexXY overexpression	G89S
423	Mpl	Recycling of cell wall components (AmpC overexpression)	R73C
424	NalC	MexAB overexpression	G71E, D79E, S209R
	NalD	MexAB overexpression	None
425	NfxB	MexCD overexpression	none (HE2011025, HE2040684) multiple (HE2011311, HE2011471, HE2105886) ²
426	OprD	Inactivation OprD	T103S, K115T, F170L, P186G, V189T, R310E, A315G, G425A
427	OprJ	MexCD overexpression	None
	OprM	Intrinsic antibiotic resistance	None
428	OprN	MexEF overexpression	S13P
	ParC	DNA topoisomerase IV (subunit A)	P752T
429	ParE	DNA topoisomerase IV (subunit B)	D533E
430	ParR	MexXY and MexEF overexpression/ OprD downregulation	S170N, L153R
431	ParS	MexXY overexpression/OprD downregulation	aa70InsPR, H398R
	PbpA	PBP2	None
	PmrA	Lipopolisaccharide synthesis	None
	PmrB	Lipopolisaccharide synthesis	S2P, A4T, V15I, G68S, Y345H

¹Mutations described previously as natural polymorphisms are in bold type

²See multiple alignment sequences using Clustal (EMBL-EBI) in Figure S2.

Table S1.

Protein	Function	Phage Infection (References)	SNP (HE2011471:HE21058)	Aminoacid change (HE2011471:HE21058)	Quorum Sensing (References)
Receptors/Pilus/Regulators/Efflux pumps Transport: Antimicrobial susceptibility					
FemA receptor	Siderophore transport Iron transport	Phage receptor (1)	G>T	A274D	(2)
TonB- dependent receptor	Antibiotic efflux. Iron transport	Phage receptor (3)	G>A	P679L	(2)
Filamentous haemagglutinin pilus	Surface adhesion	Phage receptor(4)	T>G; GGCCGGCAGTCTGCTCG GCGAGGCTCTGGACCTG CCCGCC>G; A>C; T>G; T>G	V1881G; del2874-2887; T2888P; L2890R; L2896R	(5)
Transcriptional regulator, AcrR family	Efflux pumps regulation	Phage receptor (6)	C>T	S36F	(7)
Magnesium and cobalt efflux CorC	Ion Resistance. Target of the bacteriocin	Phage receptor (8)	T>G	T213P	(9)
Quorum Sensing activation					
Acyl-homoserine lactone acylase PvdQ, quorum-quenching	Quorum sensing inhibition. Virulence	Phage Resistance (10)	GC	H695T; Q696S; L697Y; H698I; P699Q; T700L; G701V; D702T; L703F; R705E; del706708; Q709E; S711P; R712K; V713A; A714R; F716L; P718A; V719F; Q720S; R721Q; A723S	(11)

Prophages: Resistance to Lytic Phage Infection					
Zona occludens toxin	Filamentous Prophage assembly	Phage Resistance (12)	T>C	S244W; M249L; V251T; A254G; del255-280	(12)
Phage terminase, large subunit GpA	Prophage assembly	Phage Resistance (13)	Ins1-84; G>A	ins1-28; A355T	(12)
Prophage Clp protease	Prophage	Phage Resistance (14)	C>T	V134G	(15)
Small molecules: Resistance to Lytic Phage Infection					
SAM-dependent methyltransferase YafE	Aminoglycoside regulation	Phage Resistance (16)	C>T	V134G	(17)
TA systems: Resistance to Lytic Phage Infection					
HipBA toxin-antitoxin	Persistence	Phage Resistance (18)	A>C	C432R	(19)
Oxidative Stress/Secretion Systems/Virulence: Response to Lytic Phage Infection					
Flavodoxin reductases	Tolerance to oxidative stress	Phage infection (20)	C>A	R39L	(21)
Catalase KatE		Phage infection (22)	C>T	R358H	(23)
T1SS secreted agglutinin RTX	Secretion Systems	Phage infection (24)	G>T	P695T	(25)

Transcriptional anti- antiactivator ExsC T3SS		Phage infection (26)	C>T	G66E	(25)
VgrG protein Effector of the T6SS		Phage infection (27)	T>C	L32P	(25)
VgrG protein Effector of the T6SS		Phage infection (27)	A>G	V43M	(25)
Pyoverdine synthetase PvdL	Virulence	Phage infection (28)	T>G	D1938A; L2241V; L2243M; L2247I; G2252A; L2254M; L2266V; L2272E; L2275Q; Q2276A; I2279M	(29)
Cis/trans isomerase		Virulence; resistance to cell wall solvents. (30)	G>T	P82T	(31)
Isocitrate dehydrogenase [NADP]		Glyoxylate shunt linked with virulence. (32)	A>C	T474P	(33)
MOSC domain- containing protein		Molibdenum cofactor. Biosynthesis of Moco (33)	T>G	V25G	(34)
GTP 3',8-cyclase Molibdenum		Biosynthesis of Moco (35)	A>C	T257P	(34)
Phosphate synthase II PhzC (chorismate)		Phenazine biosynthesis. (36)	del765-834	del255-278	(37)

436 REFERENCES. MATERIAL SUPPLEMENTARY

437

- 438 1. Sundarrajan S, Raghupatil J, Vipra A, Narasimhaswamy N, Saravanan S,
439 Appaiah C, et al. Bacteriophage-derived CHAP domain protein, P128, kills
440 *Staphylococcus* cells by cleaving interpeptide cross-bridge of peptidoglycan.
441 Microbiology (Reading). 2014;160(Pt 10):2157-69.
- 442 2. Cornelis P, Matthijs S, Van Oeffelen L. Iron uptake regulation in
443 *Pseudomonas aeruginosa*. Biometals. 2009;22(1):15-22.
- 444 3. Rabsch W, Ma L, Wiley G, Najar FZ, Kaserer W, Schuerch DW, et al.
445 FepA- and TonB-dependent bacteriophage H8: receptor binding and genomic
446 sequence. J Bacteriol. 2007;189(15):5658-74.
- 447 4. Jouravleva EA, McDonald GA, Marsh JW, Taylor RK, Boesman-
448 Finkelstein M, Finkelstein RA. The *Vibrio cholerae* mannose-sensitive
449 hemagglutinin is the receptor for a filamentous bacteriophage from *V. cholerae*
450 O139. Infect Immun. 1998;66(6):2535-9.
- 451 5. Sun J, Li X, Qiu Y, Xue X, Zhang M, Yang W, et al. Quorum sensing
452 regulates transcription of the pilin gene mshA1 of MSHA pilus in *Vibrio*
453 *parahaemolyticus*. Gene. 2022;807:145961.
- 454 6. Nazarov PA. MDR Pumps as Crossroads of Resistance: Antibiotics and
455 Bacteriophages. Antibiotics (Basel). 2022;11(6).
- 456 7. Chin-A-Woeng TF, van den Broek D, Lugtenberg BJ, Bloemberg GV.
457 The *Pseudomonas chlororaphis* PCL1391 sigma regulator psrA represses the
458 production of the antifungal metabolite phenazine-1-carboxamide. Mol Plant
459 Microbe Interact. 2005;18(3):244-53.
- 460 8. Bohm K, Porwollik S, Chu W, Dover JA, Gilcrease EB, Casjens SR, et al.
461 Genes affecting progression of bacteriophage P22 infection in *Salmonella*
462 identified by transposon and single gene deletion screens. Mol Microbiol.
463 2018;108(3):288-305.
- 464 9. Hounmanou YMG, Leekitcharoenphon P, Hendriksen RS, Doughton TV,
465 Mdegela RH, Olsen JE, et al. Surveillance and Genomics of Toxigenic *Vibrio*
466 *cholerae* O1 From Fish, Phytoplankton and Water in Lake Victoria, Tanzania.
467 Front Microbiol. 2019;10:901.

- 468 10. León-Félix J, Villicaña C. The impact of quorum sensing on the
469 modulation of phage-host interactions. J Bacteriol. 2021.
- 470 11. Utari PD, Setroikromo R, Melgert BN, Quax WJ. PvdQ Quorum
471 Quenching Acylase Attenuates *Pseudomonas aeruginosa* Virulence in a Mouse
472 Model of Pulmonary Infection Front Cell Infect Microbiol. 2018;8:119.
- 473 12. Ambroa A, Blasco L, López-Causapé C, Trastoy R, Fernandez-García L,
474 Bleriot I, et al. Temperate Bacteriophages (Prophages) in *Pseudomonas*
475 *aeruginosa* Isolates Belonging to the International Cystic Fibrosis Clone
476 (CC274).
477 . Front Microbiol. 2020;11:556706.
- 478 13. Owen SV, Wenner N, Dulberger CL, Rodwell EV, Bowers-Barnard A,
479 Quinones-Olvera N, et al. Prophages encode phage-defense systems with
480 cognate self-immunity. Cell Host Microbe. 2021;29(11):1620-33.e8.
- 481 14. Geuskens V, Mhammedi-Alaoui A, Desmet L, Toussaint A. Virulence in
482 bacteriophage Mu: a case of trans-dominant proteolysis by the *Escherichia coli*
483 Clp serine protease. EMBO J. 1992;11(13):5121-7.
- 484 15. Yang N, Lan L. *Pseudomonas aeruginosa* Lon and ClpXP proteases:
485 roles in linking carbon catabolite repression system with quorum-sensing
486 system. Curr Genet. 2016;62(1):1-6.
- 487 16. Hardy A, Kever L, Frunzke J. Antiphage small molecules produced by
488 bacteria - beyond protein-mediated defenses. Trends Microbiol. 2023;31(1):92-
489 106.
- 490 17. Kang Y, Kim H, Goo E, Jeong H, An JH, Hwang I. Unraveling the role of
491 quorum sensing-dependent metabolic homeostasis of the activated methyl
492 cycle in a cooperative population of *Burkholderia glumae*. Sci Rep.
493 2019;9(1):11038.
- 494 18. LeRoux M, Laub MT. Toxin-Antitoxin Systems as Phage Defense
495 Elements. Annu Rev Microbiol. 2022;76:21-43.
- 496 19. Hemati S, Azizi-Jalilian F, Pakzad I, Taherikalani M, Maleki A, Karimi S,
497 et al. The correlation between the presence of quorum sensing, toxin-antitoxin
498 system genes and MIC values with ability of biofilm formation in clinical isolates
499 of *Pseudomonas aeruginosa*. Iran J Microbiol. 2014;6(3):133-9.

- 500 20. Lamb DC, Follmer AH, Goldstone JV, Nelson DR, Warrilow AG, Price
501 CL, et al. On the occurrence of cytochrome P450 in viruses. Proc Natl Acad Sci
502 U S A. 2019;116(25):12343-52.
- 503 21. Moyano AJ, Tobares RA, Rizzi YS, Krapp AR, Mondotte JA, Bocco JL, et
504 al. A long-chain flavodoxin protects *Pseudomonas aeruginosa* from oxidative
505 stress and host bacterial clearance. PLoS Genet. 2014;10(2):e1004163.
- 506 22. Mancini S, Imlay JA. The induction of two biosynthetic enzymes helps
507 *Escherichia coli* sustain heme synthesis and activate catalase during hydrogen
508 peroxide stress. Mol Microbiol. 2015;96(4):744-63.
- 509 23. Liao H, Zhong X, Xu L, Ma Q, Wang Y, Cai Y, et al. Quorum-sensing
510 systems trigger catalase expression to reverse the oxyR deletion-mediated
511 VBNC state in *Salmonella typhimurium*. Res Microbiol. 2019;170(2):65-73.
- 512 24. Zhou W, Li Y, Li Z, Ma B, Jiang X, Hu C, et al. Genomic Changes and
513 Genetic Divergence of. Front Microbiol. 2021;12:710262.
- 514 25. Pena RT, Blasco L, Ambroa A, Gonzalez-Pedrajo B, Fernandez-Garcia
515 L, Lopez M, et al. Relationship Between Quorum Sensing and Secretion
516 Systems. Front Microbiol. 2019;10:1100.
- 517 26. Nakamura K, Ogura Y, Gotoh Y, Hayashi T. Prophages integrating into
518 prophages: A mechanism to accumulate type III secretion effector genes and
519 duplicate Shiga toxin-encoding prophages in *Escherichia coli*. PLoS Pathog.
520 2021;17(4):e1009073.
- 521 27. Navarro-Garcia F, Ruiz-Perez F, Cataldi Á, Larzábal M. Type VI
522 Secretion System in Pathogenic *Yersinia*. Front Microbiol. 2019;10:1965.
- 523 28. Hosseinidoust Z, Tufenkji N, van de Ven TG. Predation in homogeneous
524 and heterogeneous phage environments affects virulence determinants of
525 *Pseudomonas aeruginosa*. Appl Environ Microbiol. 2013;79(9):2862-71.
- 526 29. Y Ramírez-Rueda R, Salvador MJ. Phenotypic detection of quorum
527 sensing inhibition in *Pseudomonas aeruginosa* pyoverdine and swarming by
528 volatile organic products. Future Microbiol. 2020;15:1147-56.
- 529 30. Bothmann H, Pluckthun A. The periplasmic *Escherichia coli* peptidylprolyl
530 cis,trans-isomerase FkpA. I. Increased functional expression of antibody
531 fragments with and without cis-prolines. J Biol Chem. 2000;275(22):17100-5.

532 31. Ünal CM, Steinert M. Microbial peptidyl-prolyl cis/trans isomerases
533 (PPIases): virulence factors and potential alternative drug targets. *Microbiol Mol*
534 *Biol Rev.* 2014;78(3):544-71.

535 32. Wang FS, Whittam TS, Selander RK. Evolutionary genetics of the
536 isocitrate dehydrogenase gene (*icd*) in *Escherichia coli* and *Salmonella*
537 *enterica*. *J Bacteriol.* 1997;179(21):6551-9.

538 33. Yan C, Li X, Zhang G, Zhu Y, Bi J, Hao H, et al. Quorum Sensing-
539 Mediated and Growth Phase-Dependent Regulation of Metabolic Pathways in
540 *Hafnia alvei* H4. *Front Microbiol.* 2021;12:567942.

541 34. Filiatrault MJ, Tomblin G, Wagner VE, Van Alst N, Rumbaugh K, Sokol
542 P, et al. *Pseudomonas aeruginosa* PA1006, which plays a role in molybdenum
543 homeostasis, is required for nitrate utilization, biofilm formation, and virulence.
544 *PLoS One.* 2013;8(2):e55594.

545 35. Shanmugam KT, Stewart V, Gunsalus RP, Boxer DH, Cole JA, Chippaux
546 M, et al. Proposed nomenclature for the genes involved in molybdenum
547 metabolism in *Escherichia coli* and *Salmonella typhimurium*. *Mol Microbiol.*
548 1992;6(22):3452-4.

549 36. Chen Y, Shen X, Peng H, Hu H, Wang W, Zhang X. Comparative
550 genomic analysis and phenazine production of *Pseudomonas chlororaphis*, a
551 plant growth-promoting rhizobacterium. *Genom Data.* 2015;4:33-42.

552 37. Wang Z, Huang X, Jan M, Kong D, Wang W, Zhang X. Lon protease
553 downregulates phenazine-1-carboxamide biosynthesis by degrading the
554 quorum sensing signal synthase PhzI and exhibits negative feedback regulation
555 of Lon itself in *Pseudomonas chlororaphis* HT66. *Mol Microbiol.*
556 2021;116(2):690-706.

557

558